Femasys (FEMY) Stock Price, News & Analysis

Company Overview

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

Key Stats

• Today's Range: $1.33 to $1.60
• 50-Day Range: $1.05 to $1.77
• 52-Week Range: $0.86 to $2.12
• Volume: 538,650 shs
• Average Volume: 269,821 shs
• Market Capitalization: $35.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

Femasys Stock Analysis - MarketRank™

Femasys scored higher than 58% of companies evaluated by MarketBeat, and ranked 478th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Femasys has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Femasys has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Femasys are expected to grow in the coming year, from ($0.86) to ($0.59) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Femasys is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Femasys is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Femasys has a P/B Ratio of 1.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.37% of the float of Femasys has been sold short.

Short Interest Ratio / Days to Cover

Femasys has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Femasys has recently increased by 120.89%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Femasys does not currently pay a dividend.

Dividend Growth

Femasys does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.37% of the float of Femasys has been sold short.

Short Interest Ratio / Days to Cover

Femasys has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Femasys has recently increased by 120.89%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.55

News Sentiment

Femasys has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Femasys this week, compared to 1 article on an average week.

Search Interest

Only 5 people have searched for FEMY on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.

MarketBeat Follows

3 people have added Femasys to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Femasys insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.32% of the stock of Femasys is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

65.27% of the stock of Femasys is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

FEMY Stock Analysis - Frequently Asked Questions

How have FEMY shares performed this year?

Femasys' stock was trading at $1.10 at the start of the year. Since then, FEMY shares have increased by 43.6% and is now trading at $1.58.
View the best growth stocks for 2025 here.

How were Femasys' earnings last quarter?

Femasys Inc. (NASDAQ:FEMY) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.20) by $0.04. The firm had revenue of $0.55 million for the quarter, compared to analysts' expectations of $0.40 million. Femasys had a negative net margin of 1,435.77% and a negative trailing twelve-month return on equity of 141.49%.

When did Femasys IPO?

Femasys (FEMY) raised $35 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 2,700,000 shares at a price of $12.00-$14.00 per share. Chardan and JonesTrading served as the underwriters for the IPO.

Who are Femasys' major shareholders?

Top institutional shareholders of Femasys include Clear Creek Financial Management LLC (1.12%), Geode Capital Management LLC (0.94%), Northern Trust Corp (0.55%) and Citadel Advisors LLC (0.18%).
View institutional ownership trends.

How do I buy shares of Femasys?

Shares of FEMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Femasys own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Femasys investors own include Sangamo Therapeutics (SGMO), Aurora Cannabis (ACB), Canoo (GOEV), FuelCell Energy (FCEL), Agenus (AGEN), Geron (GERN) and Eos Energy Enterprises (EOSE).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 3/14/2025
• Next Earnings (Estimated): 3/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:FEMY
• CIK: 1339005
• Web: www.femasys.com
• Phone: 770-500-3910
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.00
• High Stock Price Target: $12.00
• Low Stock Price Target: $8.00
• Potential Upside/Downside: +536.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.81)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-14,250,000.00
• Net Margins: -1,435.77%
• Pretax Margin: -1,435.37%
• Return on Equity: -141.49%
• Return on Assets: -82.30%

Debt

• Debt-to-Equity Ratio: 0.86
• Current Ratio: 3.94
• Quick Ratio: 3.26

Sales & Book Value

• Annual Sales: $1.26 million
• Price / Sales: 28.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.85 per share
• Price / Book: 1.85

Miscellaneous

• Outstanding Shares: 22,898,000
• Free Float: 20,077,000
• Market Cap: $35.95 million
• Optionable: Not Optionable
• Beta: -2.86